Lasse Lehtonen

Learn More
BACKGROUND Levosimendan, a novel calcium sensitiser, improves myocardial contractility without causing an increase in myocardial oxygen demand. We compared the effects of levosimendan and dobutamine on haemodynamic performance and clinical outcome in patients with low-output heart failure. METHODS Patients were recruited into a multicentre, randomised,(More)
AIMS To evaluate the safety and efficacy of levosimendan in patients with left ventricular failure complicating acute myocardial infarction. METHODS AND RESULTS Levosimendan at different doses (0.1-0.4 microg x kg(-1) x min(-1)) or placebo were administered intravenously for 6h to 504 patients in a randomised, placebo-controlled, double-blind study. The(More)
OBJECTIVES We sought to define the therapeutic dose range of levosimendan in patients with New York Heart Association class II-IV heart failure of ischemic origin. BACKGROUND Levosimendan is a calcium sensitizer for treatment of acute decompensated heart failure. METHODS A double-blind, placebo-controlled, randomized, multicenter, parallel-group study(More)
AIMS The aim of the study was to evaluate the effects on systemic and coronary haemodynamics and myocardial substrate utilization of a new calcium sensitizer, levosimendan, after coronary artery bypass grafting. METHODS AND RESULTS Twenty-three low-risk patients were included in this randomized and double-blind study. They received placebo (n = 8), 8 (n =(More)
AIMS Levosimendan, a novel calcium-dependent calcium sensitizer of the myocardial contractile proteins, also enhances diastolic relaxation and induces peripheral vasodilation by opening potassium channels. To assess the combined energetical effects of levosimendan infusion in vivo, we performed positron emission tomography in patients with decompensated(More)
Levosimendan is a new calcium sensitizer developed for the short-term intravenous treatment of congestive heart failure. The aims of the present open-label, nonrandomized study were to determine the tolerability, hemodynamic effects, and the basic pharmacokinetics of levosimendan and its metabolites during an extended continuous infusion of levosimendan.(More)
Hospital No. 64, Russian University of People’s Friendship, Moscow, Russia; Orion Pharma, Research Center, Espoo, Finland; P. Stradin’s Research and Teaching Hospital, Latvian Medical Academy, Riga, Latvia; A.L. Myasnikov Institute of Cardiology, Cardiology Research Center, Moscow, Russia; Cardiology Clinic, Sklifosovsky Research Institute for Emergency(More)
Levosimendan is a new inodilatory agent that sensitizes troponin-C in heart muscle cells to calcium, thus improving contractility. The pharmacokinetics of levosimendan were evaluated using a double-isotope technique in eight healthy volunteers and in eight patients with mild congestive heart failure (CHF). A single i.v. dose of 0.50 mg 14C-labeled(More)
AIMS The aim of this study was to characterize the population pharmacokinetics of levosimendan in patients with heart failure (NYHA grades III and IV) and its relationship to demographic factors, disease severity and concomitant use of digoxin and beta-blocking agents. METHODS Data from two efficacy studies with levosimendan administered by intravenous(More)
OBJECTIVE The objective of the study was to evaluate the pharmacokinetics, hemodynamic effects, and safety of levosimendan in children with congenital heart disease. DESIGN Open, one group, single-dose study. SETTING Cardiac catheter laboratory in a pediatric cardiology department of a university hospital. PATIENTS AND TREATMENTS: Thirteen children(More)